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Some three-dimensional quantitative structure-activity relationship (3D-QSAR) models have been constructed
using the comparative molecular field analysis (CoMFA) and comparative molecular similarity indices
(CoMSIA) for a series of 84 proline-based plus 12 structurally more diversified nonproline matrix
metalloproteinase inhibitors. The structures of these inhibitors were built from a structure template extracted
from the crystal structure of stromelysin. The structures built were divided into the training and test sets for
both the CoMFA and CoMSIA analyses for each being composed of 60 and 24 inhibitors, respectively. The
structures in the training set were aligned using some alignment rules derived from the analysis of the
Ligplot program on a recent crystal structure of ligand-collagenase-1 complex. Some stepwise CoMSIA’s
were performed on the aligned training set on which the best CoMFA result was obtained. The best CoMSIA
model was identified from the stepwise results, and the corresponding pharmacophore features were used
for the construction of a pharmacophore hypothesis by the Catalyst 4.9 program. The training set was extended
to include 11 structurally more diversified and nonproline inhibitors. To construct a pharmacophore hypothesis,
the conformation of 60 structurally aligned proline-based inhibitors was fixed, while that of the 11 structurally
more diversified nonproline inhibitors was allowed to vary during the hypothesis construction process. It
was found that the predicted activities by the top hypothesis constructed for both the training and test sets
were as good in statistics as those predicted by the best CoMSIA model from which the hypothesis was
derived. The top hypothesis was mapped onto the structures of several highly active inhibitors selected
from both the training and test sets. The goodness of mapping on each inhibitor was found to be correlated
well with the activity of each inhibitor.
INTRODUCTION
Matrix metalloproteinases (MMPs) are a family of zinc-
containing endopeptidases that mediate the degradation of
extracellular matrix of connective tissues.1 There are at least
20 enzymes that have been identified for the family, and
they are implicated in many degenerative diseases with slow
matrix degradation rate, such as cartilage loss in osteoarthri-
tis,2-4 rheumatoid arthritis,3,5,6 bone matrix degradation in
osteoporosis, or remodeling in Alzheimer disease.7 Many of
these enzymes possess the following three essential domains
namely, the propeptide domain as activation sequence, the
catalytic domain containing a conserved zinc binding motif,
and a hemopexin-like domain involving substrate recogni-
tion.8 There are three collagenases identified among these
enzymes namely, the interstitial collagenase-1 (MMP-1),9
stromelysin (MMP-3),10 and neutrophil collagenase (MMP-
8),11 and they are recognized as the key enzymes in the
pathology of matrix degradation.
Recently, numerous selective collagenase inhibitors have
been developed through a rational design process for MMP-3
and MMP-8 due to the X-ray structures of these two enzymes
being available. For example, Cheng and co-workers have
synthesized 39 piperazine-based matrix metalloproteinase
inhibitors (MMPIs) with biological activity (reported as IC50)
against MMP-3 ranging from 2.5 to 410 nM.12 Matter and
co-workers have synthesized 90 novel 2-(arylsulfonyl)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylates and -hydrox-
amates and other bicyclic rigidified analogues as inhibitors
of MMP-8.13 It is also known that several MMPIs have
progressed into clinical trials for cancers, rheumatoid,
arthritis, and osteoarthritis. However, progression through
these trials has been hindered by the appearing of muscu-
loskeletal syndrome (MSS) which manifests itself as mus-
culoskeletal pain after a few weeks of treatment.1 Inhibition
of MMP-1 has been suggested to play a role in the
appearance of MSS.2 Therefore, based on an aminopyrroli-
dine scaffold, Natchus and colleagues have designed a series
of MMP-1 inhibitors and found that some of these inhibitors
are able to protect the degradation of cartilage in a rat model
of osteoarthritis.14 Moreover, several proline-based MMPIs
designed by Cheng and colleagues also show substantial
activity against MMP-1.12
The CoMFA technique15 has emerged as an industry
standard for constructing 3D QSAR models. In using this
technique, a structural alignment rule must be established
beforehand to bring the orientation of a given molecule in
3D space relative to the other molecules in the analysis. The
electrostatic and steric interaction energies between each
ligand and a probe atom on a predefined grid are then
* Corresponding author fax: 886-3-571-5934; e-mail: thlin@
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Linear PLS Estimations (GOLPE) approaches16 have been
used by Matter and Schwab to study the binding affinity
and selectivity for 90 MMPIs synthesized for MMP-3 and
MMP-8.17 Meanwhile, Amin and Welsh have used CoMFA
to construct some 3D QSAR models for the 39 piperazine-
based MMPIs synthesized by Cheng and co-workers12 to
against MMP-3.18 In this report, we have employed several
3D QSAR techniques on the aligned structures of 30 and 54
MMPIs of MMP-1 designed respectively by Cheng et al.12
and Natchus et al.14 for constructing some 3D QSAR models
for these compounds. While both series of compounds were
derived from cis-hydroxy-D-proline, the major difference in
structural features between the two was that a sp2 center for
the former rather than a sp3 one for the latter introduced at
C-4 of the pyrrolidine ring. To explore the binding with the
subsites in the catalytic domain, S1¢ and S2¢ pockets, both
series of compounds were varied at R-4 of the aromatic
sulfonamide part or at C-4 of the pyrrolidine ring.12,14 These
proline-based inhibitors were divided into the training and
test sets. Both the training and test sets were structurally
aligned and analyzed by the CoMFA and CoMSIA methods
to derive the best 3D QSAR model for the inhibitors. Further,
the pharmacophore features obtained from the best CoMSIA
model were used to construct some pharmacophore hypoth-
eses using the Catalyst 4.9 program19 on a SGI Origin 3800
workstation equipped with 48  400 MHz MIPS R12000
processors. Some structurally more diversified nonproline
inhibitors were also included in the training set for the
construction of these pharmacophore hypotheses. The top
hypothesis thus generated was mapped onto the structures
of several highly active inhibitors selected from both the
Table 1 (Continued)
a Matrix metalloproteinase inhibitors derived from a modified proline scaffold. b New hydroxamate matrix metalloproteinase inhibitors derived
from functionalized 4-aminoprolines. c The 12 structurally more diversified nonporline MMP-1 inhibitors.
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training and test sets by the top hypothesis were found to be
as good in statistics as those predicted by the best CoMSIA
model from which the hypothesis was derived. The feasibility
of using a 3D QSAR model to assist the construction of a
pharmacophore hypothesis by the Catalyst 4.9 program19 was
discussed.
MATERIALS AND METHODS
The structures and activities of all 84 MMPIs of MMP-1
studied were listed in Table 1. Construction of structures
for these MMPIs was based on the X-ray structure 1d7x12
which contains ligand N-hydroxy-1N-(4-methoxyphenyl)-
sulfonyl-4-(Z,E-N-methoxyimino)pyrrolidine-(2R)-carboxam-
ide (inhibitor 14a of Table 1) treated as the template and
obtained from the protein data bank.20 The construction of
the molecules was done within the active site of 1d7x by
replacing side chains of the template with other groups as
has been described by others. The hydrogen atoms were
added for each structure. Each of these structures was rotated
into the coordinate frame of ligand RS2 of a MMP-1 receptor
(966C)8 before being merged with the ligand depleted
MMP-1 receptor. Each structure of the ligand-receptor
complex constructed was subjected to a brief energy
minimization using the SYBYL 6.9.1 program21 and the
Tripos60 Force Field Engine. The Gasteiger-Hu ¨ckel22 and
KOLL_ALL23 charges were deployed respectively for ligands
and receptor, and a nonbonding cutoff of 8 Å was used for
each structure complex. Each ligand structure constructed
was extracted from each structure complex using the SYBYL
Extract module.21 The total number of structures constructed
was 84 which include 30 proline- (series a)12 and 54
4-aminoproline- (series b)14 based inhibitors. The biological
activity expressed in pIC50 for the compound set was from
5.37 to 8.52. The compound set was divided into two sets,
namely, the training and test set with each containing 60
and 24 proline-based inhibitors, respectively. The structures
in the test set were selected randomly, and they were as
Figure 1. The structure of inhibitor 14a (Spc2)-MMP-1 receptor complex29 was analyzed using the Ligplot 4.22 program19 to identify
some specific contacts between atoms of ligand and receptor. The ligand atoms served as the correspondence points in the subsequent
structural alignment processes were marked with numbers alongside.
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37a, 33b, 65b, 31a, 29b, 72b, 34b, 62b, 69b, 64b, 35b, 66b, 75b,
and 12c (Table 1).
The structure of inhibitor 14a (Spc2)-MMP-1 receptor
complex8 was analyzed using the Ligplot 4.22 program24 to
identify some specific contacts between atoms of ligand and
receptor. Some of these ligand atoms were served as the
correspondence points in the subsequent structural alignment
processes. The structure of inhibitor 19a (N-hydroxy-1N-[4-
(4-fluorophenoxy)phenyl]sulfonyl-4-(Z,E-N-methoxyimino)-
pyrrolidine-(2R)-carboxamide) (Table 1) which was the most
active one among the series12 studied was chosen as the target
against which all the other structures were aligned.
The steric and electrostatic potential fields of CoMFA were
calculated at each lattice intersection for each molecule being
submerged into a regularly spaced lattice of 2.0 Å. The lattice
was extended 4 Å units beyond the van der Waals volume
of each molecule in the X, Y, and Z directions. The steric
and electrostatic fields were calculated using the Tripos force
field.25 A C.3 carbon atom with radius 1.52 Å and charge
+1.0 was used as the probe to calculate both the steric and
electrostatic fields. The truncation for both the steric and
Table 2. Stepwise Development of the Training Set CoMFA and CoMSIA Modelsa
MMP-1 cross-validation MMP-1 no validation
CoMFA MMP-1 60 CoMSIA NC q2 CF SEP r2 F
leave one out q2
loo 0.650 S 5 0.525 2 0.308 0.812 46.514
cross-validational (q2
cv) 0.649 E 3 0.283 2 0.399 0.672 38.188
conventional r2 0.954 H 4 0.648 2 0.247 0.876 97.535
standard error of estimate 0.152 D 1 0.103 2 0.651 0.096 6.136
principal components 5 A 3 0.277 2 0.449 0.585 26.280
F-values(5,54) 224.167 H + S 6 0.655 2 0.171 0.943 146.569
H + E 5 0.633 2 0.203 0.918 120.724
H + D 5 0.608 2 0.215 0.908 106.596
H + A 5 0.651 2 0.192 0.926 135.859
H + S + E 6 0.657 2 0.141 0.961 218.344
H + S + D 6 0.604 2 0.142 0.961 216.116
H + S + A* 6 0.730 2 0.157 0.952 175.639
H + S + A + D 6 0.622 2 0.134 0.964 244.380
H + S + A + E 6 0.626 2 0.149 0.957 194.251
all fields 6 0.649 2 0.166 0.946 154.599
a SEP: standard error of prediction, S: steric, E: electrostatic, H: hydrophobic, A: H-bond acceptor, D: H-bond donor H + S + A* is represented
S:H:A ) 26.0%:47.8%:26.2%.
Table 3. Information of Statistical Significance and Predictive
Power Presented in Cost Values for Top 10 Hypotheses Generated
from Three Different Approaches
set
hypothesis
no. total cost ¢cost
rms
deviation
correlation
(r)
Ia 1 235.835 25.601 0.812 0.818
2 237.133 24.303 0.828 0.810
3 239.457 21.979 0.902 0.768
4 239.554 21.882 0.873 0.787
5 239.618 21.818 0.879 0.783
6 239.699 21.737 0.880 0.783
7 240.702 20.734 0.922 0.757
8 242.147 19.289 0.947 0.741
9 242.312 19.124 0.944 0.743
10 244.042 17.394 0.984 0.716
IIb 1 252.479 16.120 1.079 0.691
2 254.958 13.641 1.113 0.666
3 255.214 13.385 1.120 0.661
4 255.297 13.302 1.120 0.661
5 255.352 13.247 1.122 0.659
6 255.521 13.078 1.125 0.657
7 255.940 12.659 1.128 0.655
8 256.595 12.004 1.141 0.645
9 256.634 11.965 1.141 0.644
10 256.733 11.866 1.142 0.643
IIIc 1 278.117 71.826 0.773 0.900
2 284.203 65.740 0.881 0.868
3 284.648 65.295 0.900 0.861
4 286.615 63.328 0.937 0.848
5 287.723 62.220 0.937 0.849
6 291.222 58.721 0.998 0.826
7 292.658 57.285 1.025 0.815
8 293.008 56.935 1.019 0.818
9 293.640 56.303 1.020 0.818
10 293.755 56.188 1.015 0.821
a I set: 60 proline-based inhibitors of MMP-1 aligned for CoMFA
and CoMSIA and without any free conformations generated for
pharmacophore hypotheses. Null cost of top-ten score hypotheses is
261.436 bits. Fixed cost is 215.016 bits. Configuration cost is 12.0748
bits. b II set: 60 proline-based inhibitors of MMP-1 aligned for CoMFA
and CoMSIA and with free conformations generated for pharmacophore
hypotheses. Null cost of top-ten score hypotheses is 268.599 bits. Fixed
cost is 217.539 bits. Configuration cost is 14.5983 bits. c III set: 60
proline-based inhibitors (without any free conformations generated) of
MMP-1 aligned for CoMFA and CoMSIA plus 11 nonproline inhibitors
with free conformations generated for pharmacophore hypotheses. Null
cost of top-ten score hypotheses is 349.943 bits. Fixed cost is 255.305
bits. Configuration cost is 15.3642 bits.
Table 4. Validation of the Hypo1 Hypothesis Using the
CatScramble Program Implemented in Catalyst Software Packagea
validation
no. total cost fixed cost
rms
deviation
correlation
(r)
configuration
cost
Results for Unscrambled
278.117 255.305 0.773 0.900 15.364
Results for Scrambled
trial 01 349.943 238.816 1.769 0.000 0.000
trial 02 345.439 253.925 1.599 0.429 13.984
trial 03 335.950 253.774 1.521 0.511 13.833
trial 04 337.302 247.226 1.580 0.452 7.285
trial 05 341.413 248.145 1.619 0.405 8.205
trial 06 349.943 238.816 1.769 0.000 0.000
trial 07 337.181 247.729 1.578 0.457 7.788
trial 08 343.542 254.880 1.577 0.455 14.939
trial 09 349.943 238.816 1.769 0.000 0.000
trial 10 335.711 246.541 1.582 0.449 6.600
trial 11 341.706 248.376 1.608 0.420 8.434
trial 12 336.356 248.620 1.570 0.462 8.680
trial 13 337.140 247.716 1.584 0.446 7.775
trial 14 336.071 247.716 1.577 0.454 7.775
trial 15 330.848 246.774 1.530 0.503 6.833
trial 16 342.425 246.281 1.634 0.386 6.340
trial 17 322.837 247.742 1.453 0.570 7.801
trial 18 347.996 247.830 1.678 0.319 7.889
trial 19 343.888 247.441 1.638 0.381 7.500
a Null cost ) 349.943.
MATRIX METALLOPROTEINASE-1 INHIBITORS J. Chem. Inf. Comput. Sci., Vol. 44, No. 5, 2004 1861Table 5. Actual and Predicted Activities of the Training Set Based on the Best Pharmacophore Hypothesis Hypo1 and CoMFA and CoMSIA
(S+H+A) Models
catalyst pharmacophore hypothesis Hypo1
MMP-1
Inh #
Act
pIC50
CoMFA
Pred pIC50
CoMSIA
S+H+A
Pred pIC50
Act IC50
(nM)
Pred IC50
(nM) error
act activity
scalea
pred activity
scalea principal
19a 8.52 8.21 8.34 3 16 5.3 +++ ++ 2
14a 8.00 7.82 7.91 10 15 1.5 ++ ++ 2
16a 7.88 8.06 7.94 13 28 2.1 ++ ++ 2
13a 7.76 7.68 7.68 17 200 12 ++ ++ 0
47b 7.76 7.54 7.56 17 18 1.1 ++ ++ 2
26b 7.72 7.46 7.41 19 53 2.8 ++ ++ 2
52b 7.72 7.57 7.60 19 22 1.2 ++ ++ 2
56b 7.69 7.76 7.63 20 18 1.1 ++ ++ 2
22a 7.69 7.70 7.81 20 11 1.8 ++ ++ 2
15a 7.65 7.84 7.74 22 32 1.4 ++ ++ 2
25a 7.61 7.74 8.15 24 33 1.4 ++ ++ 2
24a 7.58 7.33 7.44 26 41 1.6 ++ ++ 2
28a 7.48 7.39 7.38 33 47 1.4 ++ ++ 2
58b 7.37 7.35 7.39 42 24 1.7 ++ ++ 2
27b 7.13 7.26 7.14 74 62 1.2 ++ ++ 2
26a 7.12 7.24 7.00 75 93 1.2 ++ ++ 2
20a 7.09 7.31 7.13 81 70 1.2 ++ ++ 2
36a 7.06 7.25 7.22 86 120 1.4 ++ ++ 2
38b 7.06 6.88 6.88 87 410 4.8 ++ ++ 2
59b 7.00 7.03 6.95 100 330 3.3 ++ ++ 0
17a 6.96 6.70 6.59 109 36 3 ++ ++ 0
28a 6.89 6.87 6.77 127 320 2.5 ++ ++ 0
36b 6.85 6.79 6.80 140 330 2.3 ++ ++ 0
40b 6.85 6.79 6.80 140 330 2.3 ++ ++ 0
21b 6.82 6.77 6.79 150 53 2.8 ++ ++ 0
30a 6.80 7.03 6.89 155 340 2.2 ++ ++ 0
29a 6.73 6.90 6.80 184 400 2.2 ++ ++ 0
61b 6.69 6.73 6.81 200 360 1.8 ++ ++ 0
45b 6.67 6.57 6.81 210 140 1.5 ++ ++ 0
34a 6.67 6.75 6.53 212 200 1.1 ++ ++ 0
48b 6.65 6.78 6.67 220 200 1.1 ++ ++ 0
60b 6.63 6.75 6.79 230 330 1.4 ++ ++ 0
19b 6.60 6.78 6.75 250 120 2 ++ ++ 0
63b 6.58 6.46 6.56 260 170 1.5 ++ ++ 0
39b 6.58 6.44 6.62 260 150 1.7 ++ ++ 0
23b 6.58 6.84 6.84 260 370 1.4 ++ ++ 0
42b 6.56 6.67 6.59 270 330 1.2 ++ ++ 0
44b 6.55 6.66 6.60 280 190 1.4 ++ ++ 0
06a 6.53 6.50 6.67 293 200 1.5 ++ ++ 0
53b 6.52 6.57 6.57 300 250 1.2 ++ ++ 0
55b 6.50 6.63 6.57 310 200 1.5 ++ ++ 0
71b 6.45 6.41 6.43 350 330 1.1 ++ ++ 0
20b 6.42 6.30 6.36 380 320 1.2 ++ ++ 0
43b 6.35 6.40 6.42 440 320 1.4 ++ ++ 0
25b 6.34 6.25 6.14 450 1100 2.5 ++ + 0
49b 6.30 6.33 6.38 490 330 1.5 ++ ++ 0
22b 6.25 6.32 6.28 560 370 1.5 ++ ++ 0
74b 6.24 6.03 6.06 570 340 1.7 ++ ++ 0
68b 6.22 6.28 6.13 600 460 1.3 ++ ++ 0
30b 6.15 6.01 6.08 700 340 2 ++ ++ 0
70b 6.10 6.11 6.24 780 230 3.4 ++ ++ 0
07a 6.10 5.78 6.01 790 420 1.9 ++ ++ 0
50b 6.03 5.99 5.86 920 710 1.3 ++ ++ 0
41b 5.92 6.12 6.05 1200 570 2.1 ++ + 1
24b 5.88 6.03 6.18 1300 470 2.8 ++ + 1
32a 5.81 5.86 5.80 1548 2700 1.7 ++ 1
51b 5.69 5.74 5.75 2000 1400 1.4 ++ 1
46b 5.69 5.57 5.77 2000 560 3.6 ++ + 1
73b 5.53 5.66 5.43 2900 970 3 ++ + 1
35a 5.37 5.39 5.55 4235 2500 1.7 ++ 1
Inh # name or code ref
01c Marimastat 29 0.77 1.6 2.1 +++ +++ 2
02c Prinomastat 29 5.7 9 1.6 +++ +++ 2
03c BMS-275291 29 25 2 13 ++ +++ 2
04c BAY-129566 29 5000 330 15 ++ + 0
05c Cipemastat 30 3.0 4.3 1.4 +++ +++ 2
06c SC-44463 31 20 17 1.2 ++ ++ 2
07c Ilomastat 32 1.5 2.3 1.5 +++ +++ 2
08c FYK-1388 33 6.0 9.5 1.6 +++ +++ 2
09c CGS-27023A 34 33 31 1.1 ++ ++ 2
10c Ro-319790 32 3.0 16 5.2 +++ ++ 2
11c BB-3644 35 10 13 1.3 ++ ++ 2
a Activity scale: highly active (<10 nM, +++), moderately active (10-1000 nM, ++), and inactive (>1000 nM, +).
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The electrostatic contribution at the lattice intersections where
maximum steric interactions were computed was ignored.
Both the CoMFA steric and electrostatic fields computed
were scaled by the standard option given in the program.
The same lattice where each molecule was submerged for
CoMFA was used for CoMSIA. A C.3 atom of radius 1.0 Å
and charge +1 was used as the probe to compute the
CoMSIA similarity indices defined by Klebe et al.15 The
similarity indices were calculated using Gausian-type dis-
tance dependence between the probe and the atoms of the
molecules of the data set. This functional form requires no
arbitrary definition of cutoff limits and the similarity indices
can be calculated at all lattice points inside and outside the
molecule. The value of attenuation factor R was set to 0.3.
In the SYBYL CoMSIA module,26 the third power of the
atomic radii was computed as the steric indices, the atomic
partial charges were treated as the electrostatic indices, the
atom-based parameters developed by Viswanadhan et al.27
were used as the hydrophobic indices, and a rule-based
method derived experimentally28 was used as the hydrogen
bond donor and acceptor indices.
Both the CoMFA or CoMSIA results were cross-validated
using the SYBYL PLS (partial-least-squares)21 module. The
column filtering was set at 2.0 kcal/mol for reducing the
noise. The CoMFA and CoMSIA descriptors were treated
as the independent variables, while the pIC50 values were
treated as the dependent ones in all the PLS regression
analyses for deriving the 3D QSAR models. The optimum
number of components used to derive the nonvalidated model
was defined as the number of components leading to the
highest cross-validated r2 (q2) and the lowest standard error
of prediction. The non-cross-validated models were assessed
by the conventional correlation coefficient r2, standard error
of estimate, and F-values. The non-cross-validated analyses
were used to make predictions of the binding affinities of
the inhibitors from the test set and to display the coefficient
contour maps.
The structures of 12 more diversified nonproline MMP-1
inhibitors29-35 were drawn and constructed using the SYBYL
6.9.1 program21 for the purpose of external validation and
pharmacophore characterization using the Catalyst 4.9
program.19 The biological activity expressed in pIC50 was
from 5.33 to 9.11 for the compound set. Each structure in
the set was energy minimized using the CHARMM-like force
field36 within the Catalyst 4.9 program19 and subjected to a
conformational analysis using the Poling algorithm.37 All the
parameters used were default settings except that the
maximum number of conformers allowed for each molecule
was set at 250. Based on the CoMSIA results, there were
four pharmacophore features namely, E (E1,E2,E3), the three
excluded volumes; H, hydrophobic; D, hydrogen-bond donor;
and A, hydrogen-bond acceptor group; selected for the
hypothesis generation process. The pharmacophores were
manually or automatically generated for the 60 structurally
aligned proline-based MMP-1 inhibitors in the training set
or a set composed of the training set plus 11 structurally
more diversified nonproline MMP-1 inhibitors constructed
using the HypoGen module19 of the Catalyst 4.9 program.19
The top 10 scored hypotheses composed of the four phar-
macophore features for each set were exported. The signifi-
cance of the top (best) hypotheses generated was cross-
validated using the CatScramble module of the Catalyst 4.9
program.19 To obtain a 95% confidence level, 19 random
spreadsheets were generated, and every generated spreadsheet
was submitted to the HypoGen module using the same
experimental conditions (functions and parameters) as those
used in the initial run.
Table 6. Actual and Predicted Activities of the Testing Set Based on the Best Pharmacophore Hypothesis Hypo1 and CoMFA and CoMSIA
(S+H+A)
catalyst pharmacophore hypothesis Hypo1
MMP-1
Inh #
Act
pIC50
CoMFA
Pred
pIC50
CoMSIA
S+H+A
Pred pIC50
Act IC50
(nM)
Pred IC50
(nM) error
act activity
scale*
pred activity
scale*
18a 8.52 8.05 8.29 3 19 6.2 +++ ++
33a 7.82 7.25 7.22 15 120 7.6 ++ ++
57b 7.72 7.13 6.96 19 53 2.8 ++ ++
67b 7.67 7.18 7.36 21 37 1.8 ++ ++
04a 7.58 7.27 7.49 26 36 1.4 ++ ++
27a 7.49 7.42 7.31 32 65 2 ++ ++
21a 7.40 7.26 7.26 39 23 -1.7 ++ ++
23a 7.13 6.80 7.13 74 48 -1.5 ++ ++
11a 7.04 7.19 6.96 90 610 6.7 ++ ++
03a 6.92 6.89 7.08 119 500 4.2 ++ ++
37b 6.61 6.85 7.13 240 280 1.2 ++ ++
37a 6.59 6.78 6.47 255 53 -4.8 ++ ++
33b 6.56 6.53 6.69 270 100 -2.7 ++ ++
65b 6.52 6.63 6.55 300 450 1.5 ++ ++
31a 6.48 6.59 6.32 329 340 1 ++ ++
29b 6.45 7.09 6.76 350 130 -2.7 ++ ++
72b 6.31 5.99 6.24 350 340 -1 ++ ++
34b 6.30 6.73 6.99 500 390 -1.3 ++ ++
62b 6.23 6.59 6.74 580 350 -1.6 ++ ++
69b 6.12 5.93 6.06 750 110 -6.8 ++ ++
64b 6.03 6.06 6.09 920 450 -2 ++ ++
35b 5.92 6.01 6.19 1200 350 -3.4 ++ +
66b 5.74 5.52 5.77 1800 820 -2.2 ++ +
75b 5.60 6.01 5.97 2500 450 -5.5 ++ +
Inh # name or code ref
12c Batimastat 31 0.99 7.7 7.8 +++ +++
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There are three functional domains namely, the N-terminal
propeptide, the protease or catalytic, and the C-terminal
hemopexin-like domains have been characterized in MMPs.8,12
The catalytic domain is the most critical one in determining
both the MMP substrate and MMPI specificity.12 The only
significant structural differences within the catalytic domains
of various MMPs are the conformation of surface loops. The
conserved MMP core has a rms deviation of 0.3 Å when
residues 113-119, 128-133, 148-152, 160-164, 181-185,
194-198, and 211-225 of MMP-1 are superimposed with
residues 117-123, 132-137, 152-156, 164-168, 185-189,
198-202, and 215-229 of MMP-3.8 Therefore, a series of
proline-based ligands built from inhibitor 14a which is the
ligand of a MMP-3 receptor12 can be docked into the ligand-
depleted MMP-1 receptor. The structural features of the
sulfone and diphenyl parts of the two are nearly the same,
and they are superimposed well on each other (data not
shown here).
As shown in Table 1, the biological activity of the 84
MMP-1 inhibitors studied is varied with two major substitu-
tions on their structures namely, one is at the S1¢ group or
the diphenyl ether substituent and the other one is at the C-4
carbon on the proline ring.8,12,14 The former and latter
substitutions are designed for exploring the binding with the
S1¢ and S2¢ pockets of the MMP-1 receptor, respectively.
An analysis by Ligplot 4.22 program24 on the structure of
inhibitor 14a-MMP-1 complex is presented in Figure 1. The
result shows that both the diphenyl- and proline-based
substituents of 14a are properly positioned into the S1¢ and
S2¢ pockets of the receptor. In addition, one oxygen atom
of the sulfone group is positioned to serve as the hydrogen
bond acceptor to the amide nitrogens of Leu 181 (2.86 Å)
and Ala 182 (2.97 Å). The nitrogen atom of the hydroxamic
acid group of 14a also serves as hydrogen bond acceptors
with the carbonyl oxygens of Ala 182 (2.76 Å) and Glu 219
(3.47 Å). Both the carbonyl and N-hydroxyl oxygens of the
group also form a bidentate chelation with the Zn2+ ion with
distances of 3.1 and 3.22 Å, respectively (Figure 1).
However, these two distances are slightly larger than those
between the same oxygens on the original ligand RS2 with
the metal ion in which they are determined to be 1.9 and
2.1 Å, respectively.8
To proceed with 3D QSAR studies, some atoms on the
structure of inhibitor 19a which is the most active one in the
series (Table 1) are treated as the correspondence points for
Figure 2. a. The CoMFA contours obtained from the aligned structures of 60 proline-based inhibitors of the training set was mapped onto
the structure of inhibitor 19a. Green contours represent favor, while yellow ones represent disfavor regions for steric interactions. Blue
contours represent favor, while red contours represent disfavor regions for electrostatic interactions. b. The CoMSIA contours obtained
from the aligned structures of 60 proline-based inhibitors of the training set were mapped onto the structure of inhibitor 19a. Green contours
represent favor, while yellow contours represent disfavor regions for steric interactions. Purple contours represent favor, while white contours
represent disfavor regions for hydrophobic interactions. Magenta contours represent favor, while red contours represent disfavor regions for
H-bond acceptor.
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program.21 As shown in Figure 1, atoms on the proline and
phenyl rings as well as those on the sulfone and hydroxamic
acid groups are all included as the correspondence points.
Some preliminary alignments for the training set are con-
ducted by using at least three correspondence points arbi-
trarily selected in Figure 1. These aligned structural sets are
then analyzed by the SYBYL CoMFA, CoMSIA, and PLS
programs,21 and only those which give significant statistics
are kept for further analyses. The best CoMFA result of these
point alignments is presented in Table 2. The best alignment
is obtained by using all the atoms labeled in Figure 1 on the
structure of inhibitor 19a as the correspondence points. The
value of cross-validated r2 (q2) computed for the best aligned
structural set is 0.649, while that computed for the corre-
sponding conventional r2 (r2) is 0.954 (Table 2).
A stepwise CoMSIA on the 60 structurally aligned MMP-1
inhibitors in the training set for CoMFA was performed, and
the results are presented in Table 2. The five different fields
(steric denoted as S, electrostatic denoted as E, hydrophobic
denoted as H, H-bond acceptor denoted as A, and H-bond
donor denoted as D) available were chosen one by one, or
a combination of different fields was chosen for CoMSIA
on the 60 structurally aligned MMP-1 inhibitors of the
training set. As judged by q2 values computed, no statistically
significant CoMSIA result is obtained for each single field
selected except for the H one (Table 2). A combination of
H field with each of the other four ones was then conducted.
Apparently, the statistics of these results is far better than
those of the single field ones (Table 2). Since the combination
by H and S fields gives the best CoMSIA statistics among
theses results, a third step was conducted by adding each of
the rest of the three fields to the combined fields of H and
S. This step creates an even better CoMSIA result with a q2
value of 0.73 (the best CoMSIA model) due to the combina-
tion by H, S, and A fields (Table 2). However, no apparent
improvement in CoMSIA statistics is obtained for further
steps using a combination of either D or E field with the
combined H+S+A fields or even a combination of all the
five fields (Table 2). Therefore, the stepwise CoMSIA results
indicate that the interaction of the MMP-1 inhibitors of the
training set with their common receptor is best described by
a combination of H, S, and A fields. The participation of A
field is not picked by the CoMFA result. In fact, with a q2
value of 0.655, the CoMSIA result of the combined H+S
fields is nearly the same as that given by the CoMFA one
(Table 2).
To further explore the nature of pharmacophore for the
MMP-1 inhibitors, the Catalyst 4.9 program19 was used to
generate some pharmacophore hypotheses using the follow-
ing four features: the three excluded volumes (E1, E2, and
E3), hydrophobic (H), hydrogen-bond donor (D), and
hydrogen-bond acceptor (A) selected from the best stepwise
CoMSIA results. There were three types of hypotheses
generated namely, (I) hypotheses generated for the 60
structurally aligned and conformation fixed inhibitors of the
training set, (II) hypotheses generated for the 60 inhibitors
of the training set with conformations being freely generated
within the Catalyst 4.9 program,19 and (III) hypotheses
generated for a combination of the 60 structurally aligned
and conformation fixed inhibitors of the training set plus 11
structurally more diversified nonproline inhibitors (01c, 02c,
03c, 04c, 05c, 06c, 07c, 08c, 09c, 10c, and 11c) listed in Table
1 in which conformations of the latter are freely generated
within the Catalyst 4.9 program.19 A comparison for the
statistical significance of the top 10 hypotheses generated
for each type of hypotheses is given in Table 3. The two
cost differences namely between null and fixed or null and
total costs should be greater than 70 or 60, and the
configuration cost should be smaller than 17 bits for a good
hypothesis generated.19 While the configuration cost com-
puted for each hypothesis type is always smaller than 17
bits, the two cost differences computed for the top hypothesis
generated for types I, II, and III hypotheses are 25.601,
46.320; 16.120, 51.06; and 71.826, 94.638; respectively.
Therefore, only the top hypothesis of type III hypotheses
(designated as Hypo1) generated meets the criteria of being
a good hypothesis. The Hypo1 hypothesis was then cross-
Figure 3. a. The Hypo1 hypothesis is mapped onto the structure
of the most active proline-based inhibitor 19a of the training set.
The pharmacophore features are color coded as follows: black
spheres, three excluded volume (E1, E2, and E3); blue spheres,
hydrophobic (H); violet spheres, hydrogen-bond donor (D); and
green spheres, hydrogen-bond acceptor (A). b. The Hypo1 hypoth-
esis is mapped onto the structure of the most active nonproline
inhibitor 01c of the training set. The pharmacophore features are
color coded as follows: black spheres, three excluded volume (E1,
E2, and E3); blue spheres, hydrophobic (H); violet spheres,
hydrogen-bond donor (D); and green spheres, hydrogen-bond
acceptor (A).
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program.19 The validation proceeds with a random reassign-
ment of activity values e.g., generation of random spread-
sheets among the molecules of the training set. To achieve
a confidence level of 95%, 19 random spreadsheets (random
hypotheses) were generated, and the corresponding statistics
are listed in Table 4. The validation clearly shows that the
Hypo1 hypothesis is not generated by chance since its
statistics are far more superior to those of the 19 random
hypotheses generated (Table 4).
The S1¢ binding pocket of MMP-1 has been characterized
as a relative small one and whose depth is defined by Arg214
at the bottom of the pocket.8,12 Both the CoMFA and
CoMSIA contour maps also show that there are disfavor
regions for steric interaction somewhere around the tip of
the bulky diphenyl substituent on the MMP-1 inhibitors
(Figure 2a,b). The HypoRefine module of the Catalyst 4.9
program
19 was used to refine the Hypo1 hypothesis generated
since the steric interaction appears to play an important role
in the binding activity measured for the MMP-1 inhibitors.
The algorithm examines for differences in the steric interac-
tion between some active and inactive compounds selected
and labeled in the “Principal” column of the input spread-
sheet. The Hypo1 hypothesis was built based on the
structures of 71 MMP-1 inhibitors where the 28 most and 7
least active compounds were chosen as “Active” (labeled
with digit 2) or “Inactive” (labeled with digit 1) by the
HypoRefine run (Tables 5 and 6). The refined Hypo1
hypothesis was mapped onto the structures of the two most
active inhibitors 19a and 01c (Table 1) in the training set,
and the results are presented in Figure 3 (parts a and b,
respectively). The CoMFA and CoMSIA contour maps agree
with each other on the identification of favor regions for
steric interaction (displayed with green contours by both
CoMFA and CoMSIA) and which are around the diphenyl
substituent or around the tip of the hydroxamic acid group
(Figure 2a,b). The favor regions for electrostatic interaction
identified by CoMFA (displayed with blue contours) also
agree with the disfavor regions for hydrophobic interaction
identified by CoMSIA (displayed with white contours) which
are around the oxime substituent on the pyrrolidine ring or
the hydroxamic acid group (Figure 2a,b). However, the favor
or disfavor regions for hydrogen-bond acceptor are only
picked by CoMSIA and are around the hydroxamic acid
group (Figure 2b). This would agree with those given by
the Hypo1 hypothesis where the structure of inhibitor 19a is
mapped (Figure 3a) since both features of hydrogen-bond
donor (displayed by violet spheres) and hydrogen-bond
acceptor (displayed by green spheres) are identified to be
around the hydroxamic acid group. The features of hydro-
phobic (displayed by blue spheres) and excluded volumes
(displayed by black spheres) of the Hypo1 hypothesis (Figure
3a) are also matched with those given by the CoMSIA
contours (Figure 2b) where the former is expressed with
Figure 4. The regression of actual versus predicted activities by the Hypo1 hypothesis for the training set inhibitors onto a linear relationship.
The training set includes 60 proline-based plus 11 nonproline inhibitors.
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ring and the latter is represented with yellow contours
(disfavor region for steric) around the diphenyl substituent.
The Hypo1 hypothesis was also mapped onto the structure
of 01c, the most active compound of the 11 structurally more
diversified nonproline based MMP-1 inhibitors (Table 1)
being used for the construction of the hypothesis. There are
two hydroxyl groups on the structure, and both are correctly
mapped onto the violet spheres representing the feature of
hydrogen-bond donor (Figure 3b). Both the 2-methylbutane
and methylamine moieties of the inhibitor are also identified
as the favor regions of three excluded volume (black spheres)
or hydrophobic (blue sphere).
The C-4 substituent namely, the C)X bond (Table 1) on
the proline ring is flat or in sp2 orientation which is extended
into the S2¢ surface pocket of the MMP-1 receptor and is
also considered to be hydrophobic.12-14 It has been suggested
that these substituents could not directly affect the overall
binding but would alter the conformation of proline ring to
a more efficiently bound orientation.12 This feature is also
identified by the Hypo1 hypothesis on inhibitor 01c in which
a blue sphere is mapped onto the methylamine group of the
Figure 5. The regression of actual versus predicted activities by the Hypo1 hypothesis for the test set inhibitors onto a linear relationship.
The test set includes 24 proline-based plus 1 nonproline inhibitors.
Table 7. Mapping of Hypo1 Hypothesis to Several Highly Active Inhibitors Selected from Both the Training and Test Sets
Inh # E1 E2 -E3 H D A
01c (+++)a methylamine 2-methylbutane C23 (0.15)b O8 (0.28,0.51)b O17 (0.43,0.23)b
12c (+++) N-methyl-acetamide N-hydroxy-acetamide C29 (0.14) O17 (0.17,0.51) S10 (0.86,1.30)
07c (+++)a N-methyl-formamide 3-methyl-1H-indole C16 (0.19) N13 (0.08,0.84) O28 (0.29,0.67)
05c (+++)a 1-piperidin-1-yl-ethanone N-hydroxy-acetamide piperidine (0.19) O19 (0.16,0.62) O26 (0.78,0.90)
18a (++) O-methyl-hydroxylamine methoxybenzene C23 (0.34) O19 (0.42,0.49) O8 (1.16,1.17)
02c (+++)a 4-methylpyridine N-hydroxy-formamide pyridine (0.11) O21 (0.90,0.86) O2 (0.71,0.70)
08c (+++)a butylbenzene N-hydroxy-acetamide benzene (0.25) O17 (0.77,1.17) O8 (0.59,0.69)
14a (++)a 1-methoxy-4-methyl-benzene N-hydroxy-formamide C11 (0.27) N18 (0.54,1.37) O8 (0.83,0.79)
16a (++)a O-methyl-hydroxylamine 3-phenoxy-propan-1-ol C23 (0.21) O19 (0.64,0.49) O8 (1.13,1.42)
33a (++) 1-methyl-4-phenoxybenzene N-hydroxy-acetamide benzene (0.23) N18 (0.70,2.25) O8 (0.88,0.59)
57b (++) methoxybenzene N-hydroxy-acetamide benzene (0.33) N18 (0.82,1.77) O8 (0.67,1.00)
06c (++)a 1-methoxy-4-methylbenzene N-methyl-acetamide benzene (0.07) O27 (0.78,0.89) O23 (0.97,1.02)
67b (++) methoxybenzene N-hydroxy-acetamide benzene (0.27) N18 (0.77,1.87) O8 (0.70,0.48)
03c (+++)a isobutane 2-methylbutane C34 (0.05) S8 (0.42,0.50) O9 (0.43,0.55)
04a (++) pentane N-hydroxy-acetamide C23 (0.17) N18 (0.53,1.61) N21 (0.83,1.22)
04c (++)a benzenethiol 4¢-chloro-4-methylbiphenyl benzene (0.02) (not mapped) O3 (0.06,0.19)
a The representative of testing set. b Hydrophobic (H); hydrogen-bond donor (D); and hydrogen-bond acceptor (A) displacement of the feature
from the center of the location constraint.
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activities by the best CoMFA (Table 2 and Figure 2a) and
CoMSIA (Table 2 and Figure 2b) models and the Hypo1
hypothesis for each training set inhibitors are listed and
compared in Table 5, while those for test set inhibitors are
given in Table 6, respectively. Regression of the predicted
activities for both the training and test sets by the best
CoMSIA model onto a linear relationship versus the actual
ones gives correlation coefficients R2 of 0.952 and 0.836,
respectively. The regression results by the same relationship
for those predicted by the Hypo1 hypothesis are shown in
Figures 4 and 5 for the training and test set inhibitors,
respectively. The corresponding R2 values obtained for each
plot are 0.900 and 0.834 (Figures 4 and 5), respectively. This
indicates that the prediction results given by the best
CoMSIA model are well reproduced by the Hypo1 hypoth-
esis constructed using the pharmacophore features selected
by the best CoMSIA model. Note that most of the highly
active inhibitors correctly predicted by the Hypo1 hypothesis
are the 11 structurally more diversified nonproline inhibitors
of the training set (Table 5). Moreover, the only structurally
more diversified nonproline inhibitor grouped into the test
set is inhibitor 12c and which is also correctly predicted by
Hypo1 hypothesis as a highly active compound (Table 6).
Figure 6. The mapping of Hypo1 hypothesis onto the structures of 6 highly active nonproline inhibitors (02c, 03c, 05c, 07c, 08c, and 12c)
selected from both the training and test sets. The pharmacophore features are color coded as follows: black spheres, three excluded volume
(E1, E2, and E3); blue spheres, hydrophobic (H); violet spheres, hydrogen-bond donor (D); and green spheres, hydrogen-bond acceptor
(A).
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some highly and medium active inhibitors predicted for both
the training and test sets is presented in Table 7. The
inhibitors listed from top to bottom in the table are arranged
in the order of actual activities measured. The following 8
inhibitors namely, 01c, 12c, 07c, 05c, 18a, 02c, 08c, and 14a,
are considered as highly active since their pIC50 values
measured are greater than 8.0 (Tables 1 and 7). Apparently,
most of these highly active inhibitors are predicted by the
Hypo1 hypothesis as highly active and labeled with the the
‘+++’ scale (Table 7). The only two inhibitors predicted
incorrectly and labeled with the ‘++’ scale are the proline-
based ones namely 18a and 14a (Tables 1 and 7). However,
there is also a medium active inhibitor namely 03c being
incorrectly predicted by the Hypo1 hypothesis as highly
active and labeled with the ‘+++” scale (Table 7). There-
fore, the overall percentage of correct prediction by the
Hypo1 hypothesis for these inhibitors is 81% (Table 7). Each
of the structural features of the Hypo1 hypothesis is also
mapped correctly onto the corresponding functional group
of each inhibitor as can be judged by the displacement values
parenthesized underneath each functional group (Table 7).
The mapping of Hypo1 hypothesis onto the structures of 6
highly active nonproline based inhibitors 02c, 03c, 05c, 07c,
08c, and 12c is also presented in Figure 6. The most
diversified structural features of these nonproline based
inhibitors are identified by the Hypo1 hypothesis as the
regions mapped with the three excluded volume (represented
with the black spheres) (Table 7 and Figure 6). These regions
may be worth further exploration since not much difference
is found in the mapping of other structural features of these
inhibitors by the Hypo1 hypothesis. A further validation for
the Hypo1 hypothesis is also performed by docking the most
active inhibitor 01c studied into the active site of the MMP-1
receptor (PDB entry 966c)8 using the DOCK 4.0.2 pro-
gram.38,39 The pocket for the active site is constructed by
including all the residue atoms that are within a distance of
6 Å from every ligand atom. While Gasteiger-Hu ¨ckel22
charges are assigned for each ligand atom, the AMBER95
charges40 are used for each receptor one. The parameters of
the flexible docking process such as the maximum anchor
orientations and configuration per cycle are set as 300 and
50, respectively. The Hypo1 hypothesis is then mapped onto
the docked conformation of inhibitor 01c, and the result is
presented in Figure 7. The predicted pIC50 by the Catalyst
program19 for the mapped inhibitor is 2.21 which is in close
agreement with that given for the original conformation of
the same compound (see Figure 3b and Table 5). Except
the D (hydrogen-bond donor) feature, both the H (hydro-
phobic) and A (hydrogen-bond acceptor) features of the two
conformations are well matched (Figures 3b and 7), indicat-
ing that the Hypo1 hypothesis constructed can be used to
represent the MMP-1 receptor.
CONCLUSION
In this report we have shown that structural features
extracted from a 3D QSAR model can be used to assist the
construction of a top pharmacophore hypothesis by the
Catalyst program. The two most commonly used methods
for building a 3D QSAR model are CoMFA and CoMSIA.
While each of the two has its own merit, we found that the
latter one is more versatile in identifying some important
molecular features contributed to the overall activity of a
molecule analyzed. However, both rely on the preliminary
structure alignment and have a limitation on the use of
structurally more diversified molecules in the analysis. The
disadvantages may be complemented by using the Catalyst
program, a pharmacophore hypothesis building method
which allows the identification of structural features from
numerous conformations generated for a series of molecules
studied. No preliminary structure alignment is required for
the series of molecules analyzed by the method. The statistics
or the correlation coefficient R2 of a linear regression model
of the predicted versus actual activities given by the Catalyst
program was around 0.6 if free conformations for all the 60
proline-based inhibitors of the training set were used in the
hypothesis generation process. However, these statistics were
enhanced to 0.8 if fixed or aligned conformations for all the
60 proline-based inhibitors were used in the hypothesis
generation process. This reveals that one cannot simply count
on the generation of a variety of conformations to achieve
the construction of a better pharmacophore hypothesis. By
including 11 structurally more diversified nonproline inhibi-
tors in the training set and by allowing the conformations of
only these inhibitors to change freely during the hypothesis
generation process, a top hypothesis of R2 of 0.9 was
constructed.
The other difficulty encountered in using the Catalyst
program is to choose some representative pharmacophoe
features for building a hypothesis. The task is laborious since
there are 11 default features provided by the program, and
only some of them are selected in one run. We are aware of
a recent development of some 4D-QSAR techniques41,42 in
choosing the representative pharmacophore features for
building a hypothesis. However, we have shown here that a
top hypothesis can be constructed using some structural
features extracted from some stepwise CoMSIA models.
These CoMSIA features are produced from the fixed or
aligned conformation of 60 proline-based inhibitors and may
be essential for the activities of these molecules. These
CoMSIA features may be slightly modified in the top
hypothesis generated since some structurally more diversified
nonproline inhibitors were added into the hypothesis genera-
tion process. A hypothesis generated using structures of
Figure 7. The Hypo1 hypothesis is mapped onto the flexibly
docked conformation of inhibitor 01c.
MATRIX METALLOPROTEINASE-1 INHIBITORS J. Chem. Inf. Comput. Sci., Vol. 44, No. 5, 2004 1869purely nonproline inhibitors would not achieve the best
prediction accuracy of the top hypothesis. Most of the
nonproline inhibitors are more active than those of the
proline-based ones, and yet they are better predicted by the
top hypothesis constructed from the CoMSIA features
extracted from the proline-based ones.
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